1. INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE. (12th June 2019) Authors: Ansell, S.M.; Bartlett, N.L.; Chen, R.W.; Herrera, A.; Domingo‐Domenech, E.; Mehta, A.; Forero‐Torres, A.; Garcia‐Sanz, R.; Armand, P.; Devata, S.; Rodriguez Izquierdo, A.; Lossos, I.S.; Reeder, C.B.; Sher, T.; Choe‐Juliak, C.; Prier, K.; Schwarz, S.E.; Strassz, A.; Alland, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 177 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL). (12th June 2019) Authors: Budde, L.E.; Vallurupalli, A.; Babu, S.; Lossos, I.S.; Alderuccio, J.P.; Chavez, J.C.; Eradat, H.; Holmes, H.; Hamadani, M.; Karur, V.G.; Olszewski, A.J.; Seymour, E.; Althaus, B.; Medeiros, B.M.; Li, C.C.; Kwan, A.; Wei, M.C.; Yin, S.; O'Hear, C.; Munoz, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗